LABELS · 161cb5e7-7955-45e5-bdde-9be94fdbe76a

CYRAMZA

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-06-09
Captured: 2026-09-09T23:37:39.774134+00:00
Current indication reconciliation: Not reconciled

Indications and usage: exact source text

1 INDICATIONS AND USAGE CYRAMZA ® is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated: as a single agent or in combination with paclitaxel, for treatment of adults with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. ( 1.1 ) in combination with erlotinib, for first-line treatment of adults with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. ( 1.2 ) in combination with docetaxel, for treatment of adults with metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA. ( 1.2 ) in combination with FOLFIRI, for the treatment of adults with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. ( 1.3 ) as a single agent, for the treatment of adults with hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib. ( 1.4 ) 1.1 Gastric Cancer CYRAMZA ® , as a single agent or in combination with paclitaxel, is indicated for the treatment of adults with advanced or metastatic, gastric or gastro-esophageal junction (GEJ) adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. 1.2 Non-Small Cell Lung Cancer CYRAMZA, in combination with erlotinib, is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. CYRAMZA, in combination with docetaxel, is indicated for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. Patients with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA. 1.3 Colorectal Cancer CYRAMZA, in combination with FOLFIRI (irinotecan, folinic acid, and fluorouracil), is indicated for the treatment of adults with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. 1.4 Hepatocellular Carcinoma CYRAMZA, as a single agent, is indicated for the treatment of adults with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of ≥400 ng/mL and have been treated with sorafenib.

Full extracted label fields

application numbers

BLA125477

boxed warning exact

brand names

CYRAMZA

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c6080942-dee6-423e-b688-1272c2ae90d4

generic names

RAMUCIRUMAB

161cb5e7-7955-45e5-bdde-9be94fdbe76a

indications and usage exact

1 INDICATIONS AND USAGE CYRAMZA ® is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated: as a single agent or in combination with paclitaxel, for treatment of adults with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. ( 1.1 ) in combination with erlotinib, for first-line treatment of adults with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. ( 1.2 ) in combination with docetaxel, for treatment of adults with metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA. ( 1.2 ) in combination with FOLFIRI, for the treatment of adults with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. ( 1.3 ) as a single agent, for the treatment of adults with hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib. ( 1.4 ) 1.1 Gastric Cancer CYRAMZA ® , as a single agent or in combination with paclitaxel, is indicated for the treatment of adults with advanced or metastatic, gastric or gastro-esophageal junction (GEJ) adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. 1.2 Non-Small Cell Lung Cancer CYRAMZA, in combination with erlotinib, is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. CYRAMZA, in combination with docetaxel, is indicated for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. Patients with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA. 1.3 Colorectal Cancer CYRAMZA, in combination with FOLFIRI (irinotecan, folinic acid, and fluorouracil), is indicated for the treatment of adults with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. 1.4 Hepatocellular Carcinoma CYRAMZA, as a single agent, is indicated for the treatment of adults with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of ≥400 ng/mL and have been treated with sorafenib.

indications and usage tables exact

is original packager

true

manufacturer names

Eli Lilly and Company

matched search terms

cancer
carcinoma
lymphoma
tumor
tumors

package ndcs

0002-7669-01
0002-7678-01

product ndcs

0002-7669
0002-7678

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

INTRAVENOUS

rxcuis

1657775
1657777
1657780
1657781

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00000.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

BLA125477

brand names

CYRAMZA

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 577
end exclusive: true
exact text: 1 INDICATIONS AND USAGE CYRAMZA ® is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated: as a single agent or in combination with paclitaxel, for treatment of adults with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. ( 1.1 ) in combination with erlotinib, for first-line treatment of adults with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R)
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 0

current approval status

not_reconciled

duplicate text group

dup-a00c1ade3761c047670e

extraction review status

automated_candidate_pending_source_review

generic names

RAMUCIRUMAB

ind-span-fd48671b1fc49895d466

label id

161cb5e7-7955-45e5-bdde-9be94fdbe76a

positive predicate support span

end: 120
end exclusive: true
exact text: is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 34

qualifier mentions

context exact
e agent or in combination with paclitaxel, for treatment of adults with advanced or metastatic gastric or gastro-esophageal ju
kind
age
polarity
not_inferred
span
end
198
end exclusive
true
exact text
adults
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
192
context exact
n with paclitaxel, for treatment of adults with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after pr
kind
biomarker
polarity
not_inferred
span
end
259
end exclusive
true
exact text
metastatic gastric or gastro-esophageal jun
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
216
context exact
n combination with paclitaxel, for treatment of adults with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on
kind
stage_or_setting
polarity
not_inferred
span
end
247
end exclusive
true
exact text
advanced or metastatic gastric or gastro-es
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
204
context exact
ial growth factor receptor 2 (VEGFR2) antagonist indicated: as a single agent or in combination with paclitaxel, for treatment of adults with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-contai
kind
regimen
polarity
not_inferred
span
end
299
end exclusive
true
exact text
as a single agent or in combination with paclitaxel, for treatment of adults with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progre
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
122

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
non-small cell lung cancer
definition span
end
1794
end exclusive
true
exact text
non-small cell lung cancer (NSCLC)
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
1760

source span

end: 377
end exclusive: true
exact text: 1 INDICATIONS AND USAGE CYRAMZA ® is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated: as a single agent or in combination with paclitaxel, for treatment of adults with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22161cb5e7-7955-45e5-bdde-9be94fdbe76a%22

spl effective date

2026-06-09

spl set id

c6080942-dee6-423e-b688-1272c2ae90d4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 2 · unclassified context

application numbers

BLA125477

brand names

CYRAMZA

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 585
end exclusive: true
exact text: treatment of adults with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. ( 1.1 ) in combination with erlotinib, for first-line treatment of adults with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutation
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 178

current approval status

not_reconciled

duplicate text group

dup-cf77cec6eadf5cf4cb25

extraction review status

automated_candidate_pending_source_review

generic names

RAMUCIRUMAB

ind-span-11d6183e1ffe3cc13ec7

label id

161cb5e7-7955-45e5-bdde-9be94fdbe76a

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
non-small cell lung cancer
definition span
end
1794
end exclusive
true
exact text
non-small cell lung cancer (NSCLC)
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
1760

source span

end: 385
end exclusive: true
exact text: ( 1.1 )
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 378

source url

https://api.fda.gov/drug/label.json?search=id%3A%22161cb5e7-7955-45e5-bdde-9be94fdbe76a%22

spl effective date

2026-06-09

spl set id

c6080942-dee6-423e-b688-1272c2ae90d4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 3 · positive indication candidate

application numbers

BLA125477

brand names

CYRAMZA

classification reasons

inherited_predicate_from_same_label_section_requires_review
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 787
end exclusive: true
exact text: nt of adults with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. ( 1.1 ) in combination with erlotinib, for first-line treatment of adults with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. ( 1.2 ) in combination with docetaxel, for treatment of adults with metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK g
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 186

current approval status

not_reconciled

duplicate text group

dup-6ed5eedbde89b64000d8

extraction review status

automated_candidate_pending_source_review

generic names

RAMUCIRUMAB

ind-span-ffede079ec35899ed5e3

label id

161cb5e7-7955-45e5-bdde-9be94fdbe76a

positive predicate support span

end: 120
end exclusive: true
exact text: is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 34

qualifier mentions

context exact
in combination with erlotinib, for first-line treatment of adults with metastatic non-small cell lung cancer with epidermal g
kind
age
polarity
not_inferred
span
end
451
end exclusive
true
exact text
adults
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
445
context exact
ion with erlotinib, for first-line treatment of adults with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or
kind
biomarker
polarity
not_inferred
span
end
500
end exclusive
true
exact text
metastatic non-small cell lung cancer with
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
457
context exact
all cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.
kind
biomarker
polarity
not_inferred
span
end
578
end exclusive
true
exact text
EGFR) exon 19 deletions or exon 21 (L858R) m
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
534
context exact
ion with erlotinib, for first-line treatment of adults with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or e
kind
stage_or_setting
polarity
not_inferred
span
end
502
end exclusive
true
exact text
metastatic non-small cell lung cancer with ep
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
457
context exact
in combination with erlotinib, for first-line treatment of adults with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.
kind
prior_therapy_or_line
polarity
not_inferred
span
end
586
end exclusive
true
exact text
first-line treatment of adults with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
421
context exact
in combination with erlotinib, for first-line treatment of adults with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.
kind
regimen
polarity
not_inferred
span
end
565
end exclusive
true
exact text
in combination with erlotinib, for first-line treatment of adults with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
386

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
non-small cell lung cancer
definition span
end
1794
end exclusive
true
exact text
non-small cell lung cancer (NSCLC)
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
1760

source span

end: 587
end exclusive: true
exact text: in combination with erlotinib, for first-line treatment of adults with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 386

source url

https://api.fda.gov/drug/label.json?search=id%3A%22161cb5e7-7955-45e5-bdde-9be94fdbe76a%22

spl effective date

2026-06-09

spl set id

c6080942-dee6-423e-b688-1272c2ae90d4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 4 · unclassified context

application numbers

BLA125477

brand names

CYRAMZA

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 795
end exclusive: true
exact text: combination with erlotinib, for first-line treatment of adults with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. ( 1.2 ) in combination with docetaxel, for treatment of adults with metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic t
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 388

current approval status

not_reconciled

duplicate text group

dup-01efd3c6805f2383d64b

extraction review status

automated_candidate_pending_source_review

generic names

RAMUCIRUMAB

ind-span-f600fbc0b4cb196f7731

label id

161cb5e7-7955-45e5-bdde-9be94fdbe76a

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
non-small cell lung cancer
definition span
end
1794
end exclusive
true
exact text
non-small cell lung cancer (NSCLC)
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
1760

source span

end: 595
end exclusive: true
exact text: ( 1.2 )
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 588

source url

https://api.fda.gov/drug/label.json?search=id%3A%22161cb5e7-7955-45e5-bdde-9be94fdbe76a%22

spl effective date

2026-06-09

spl set id

c6080942-dee6-423e-b688-1272c2ae90d4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 5 · positive indication candidate

application numbers

BLA125477

brand names

CYRAMZA

classification reasons

inherited_predicate_from_same_label_section_requires_review
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 959
end exclusive: true
exact text: tion with erlotinib, for first-line treatment of adults with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. ( 1.2 ) in combination with docetaxel, for treatment of adults with metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA. ( 1.2 ) in combination with FOLFIRI, for
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 396

current approval status

not_reconciled

duplicate text group

dup-0ba7e94baac7c22b8df3

extraction review status

automated_candidate_pending_source_review

generic names

RAMUCIRUMAB

ind-span-5fc1794b5111c5616331

label id

161cb5e7-7955-45e5-bdde-9be94fdbe76a

positive predicate support span

end: 120
end exclusive: true
exact text: is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 34

qualifier mentions

context exact
in combination with docetaxel, for treatment of adults with metastatic non-small cell lung cancer with disease pro
kind
age
polarity
not_inferred
span
end
650
end exclusive
true
exact text
adults
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
644
context exact
in combination with docetaxel, for treatment of adults with metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy.
kind
biomarker
polarity
not_inferred
span
end
699
end exclusive
true
exact text
metastatic non-small cell lung cancer with
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
656
context exact
in combination with docetaxel, for treatment of adults with metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy.
kind
stage_or_setting
polarity
not_inferred
span
end
701
end exclusive
true
exact text
metastatic non-small cell lung cancer with di
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
656
context exact
in combination with docetaxel, for treatment of adults with metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy.
kind
regimen
polarity
not_inferred
span
end
758
end exclusive
true
exact text
in combination with docetaxel, for treatment of adults with metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
596

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
non-small cell lung cancer
definition span
end
1794
end exclusive
true
exact text
non-small cell lung cancer (NSCLC)
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
1760

source span

end: 759
end exclusive: true
exact text: in combination with docetaxel, for treatment of adults with metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy.
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 596

source url

https://api.fda.gov/drug/label.json?search=id%3A%22161cb5e7-7955-45e5-bdde-9be94fdbe76a%22

spl effective date

2026-06-09

spl set id

c6080942-dee6-423e-b688-1272c2ae90d4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 6 · positive indication candidate

application numbers

BLA125477

brand names

CYRAMZA

classification reasons

inherited_predicate_from_same_label_section_requires_review
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1117
end exclusive: true
exact text: exon 21 (L858R) mutations. ( 1.2 ) in combination with docetaxel, for treatment of adults with metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA. ( 1.2 ) in combination with FOLFIRI, for the treatment of adults with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimi
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 560

current approval status

not_reconciled

duplicate text group

dup-7bdd27ba5190415dd104

extraction review status

automated_candidate_pending_source_review

generic names

RAMUCIRUMAB

ind-span-cc79e9d49d8fbd09b4c3

label id

161cb5e7-7955-45e5-bdde-9be94fdbe76a

positive predicate support span

end: 120
end exclusive: true
exact text: is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 34

qualifier mentions

context exact
Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these
kind
biomarker
polarity
not_inferred
span
end
818
end exclusive
true
exact text
EGFR or ALK genomic tumor aberrations should
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
774

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
non-small cell lung cancer
definition span
end
1794
end exclusive
true
exact text
non-small cell lung cancer (NSCLC)
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
1760

source span

end: 917
end exclusive: true
exact text: Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA.
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 760

source url

https://api.fda.gov/drug/label.json?search=id%3A%22161cb5e7-7955-45e5-bdde-9be94fdbe76a%22

spl effective date

2026-06-09

spl set id

c6080942-dee6-423e-b688-1272c2ae90d4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 7 · unclassified context

application numbers

BLA125477

brand names

CYRAMZA

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1125
end exclusive: true
exact text: on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA. ( 1.2 ) in combination with FOLFIRI, for the treatment of adults with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. (
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 718

current approval status

not_reconciled

duplicate text group

dup-01efd3c6805f2383d64b

extraction review status

automated_candidate_pending_source_review

generic names

RAMUCIRUMAB

ind-span-d9f621e2e2c5009f1c5a

label id

161cb5e7-7955-45e5-bdde-9be94fdbe76a

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
non-small cell lung cancer
definition span
end
1794
end exclusive
true
exact text
non-small cell lung cancer (NSCLC)
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
1760

source span

end: 925
end exclusive: true
exact text: ( 1.2 )
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 918

source url

https://api.fda.gov/drug/label.json?search=id%3A%22161cb5e7-7955-45e5-bdde-9be94fdbe76a%22

spl effective date

2026-06-09

spl set id

c6080942-dee6-423e-b688-1272c2ae90d4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · unclassified context

application numbers

BLA125477

brand names

CYRAMZA

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1322
end exclusive: true
exact text: fter platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA. ( 1.2 ) in combination with FOLFIRI, for the treatment of adults with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. ( 1.3 ) as a single agent, for the treatment of adults with hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib. ( 1.4 ) 1.1 Gastric
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 726

current approval status

not_reconciled

duplicate text group

dup-f98fb664fe1167037071

extraction review status

automated_candidate_pending_source_review

generic names

RAMUCIRUMAB

ind-span-36fb9e56458a7341659a

label id

161cb5e7-7955-45e5-bdde-9be94fdbe76a

positive predicate support span

Source null

qualifier mentions

context exact
in combination with FOLFIRI, for the treatment of adults with metastatic colorectal cancer with disease progression
kind
age
polarity
not_inferred
span
end
982
end exclusive
true
exact text
adults
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
976
context exact
combination with FOLFIRI, for the treatment of adults with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxali
kind
biomarker
polarity
not_inferred
span
end
1031
end exclusive
true
exact text
metastatic colorectal cancer with disease p
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
988
context exact
combination with FOLFIRI, for the treatment of adults with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxalipl
kind
stage_or_setting
polarity
not_inferred
span
end
1033
end exclusive
true
exact text
metastatic colorectal cancer with disease pro
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
988
context exact
in combination with FOLFIRI, for the treatment of adults with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.
kind
regimen
polarity
not_inferred
span
end
1105
end exclusive
true
exact text
in combination with FOLFIRI, for the treatment of adults with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
926

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
non-small cell lung cancer
definition span
end
1794
end exclusive
true
exact text
non-small cell lung cancer (NSCLC)
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
1760

source span

end: 1122
end exclusive: true
exact text: in combination with FOLFIRI, for the treatment of adults with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 926

source url

https://api.fda.gov/drug/label.json?search=id%3A%22161cb5e7-7955-45e5-bdde-9be94fdbe76a%22

spl effective date

2026-06-09

spl set id

c6080942-dee6-423e-b688-1272c2ae90d4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 9 · unclassified context

application numbers

BLA125477

brand names

CYRAMZA

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1330
end exclusive: true
exact text: ) in combination with FOLFIRI, for the treatment of adults with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. ( 1.3 ) as a single agent, for the treatment of adults with hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib. ( 1.4 ) 1.1 Gastric Cancer C
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 923

current approval status

not_reconciled

duplicate text group

dup-694739559931cebfa992

extraction review status

automated_candidate_pending_source_review

generic names

RAMUCIRUMAB

ind-span-d311f6dbf26717dc5eb8

label id

161cb5e7-7955-45e5-bdde-9be94fdbe76a

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
non-small cell lung cancer
definition span
end
1794
end exclusive
true
exact text
non-small cell lung cancer (NSCLC)
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
1760

source span

end: 1130
end exclusive: true
exact text: ( 1.3 )
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 1123

source url

https://api.fda.gov/drug/label.json?search=id%3A%22161cb5e7-7955-45e5-bdde-9be94fdbe76a%22

spl effective date

2026-06-09

spl set id

c6080942-dee6-423e-b688-1272c2ae90d4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 10 · unclassified context

application numbers

BLA125477

brand names

CYRAMZA

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1501
end exclusive: true
exact text: mbination with FOLFIRI, for the treatment of adults with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. ( 1.3 ) as a single agent, for the treatment of adults with hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib. ( 1.4 ) 1.1 Gastric Cancer CYRAMZA ® , as a single agent or in combination with paclitaxel, is indicated for the treatment of adults with advanced or metastatic, gastric or gastro-esophageal junction
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 931

current approval status

not_reconciled

duplicate text group

dup-eb93e7961484dda605a8

extraction review status

automated_candidate_pending_source_review

generic names

RAMUCIRUMAB

ind-span-498395e542a38b9f7433

label id

161cb5e7-7955-45e5-bdde-9be94fdbe76a

positive predicate support span

Source null

qualifier mentions

context exact
as a single agent, for the treatment of adults with hepatocellular carcinoma in patients who have an alpha
kind
age
polarity
not_inferred
span
end
1177
end exclusive
true
exact text
adults
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
1171
context exact
as a single agent, for the treatment of adults with hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib.
kind
regimen
polarity
not_inferred
span
end
1300
end exclusive
true
exact text
as a single agent, for the treatment of adults with hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
1131

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
non-small cell lung cancer
definition span
end
1794
end exclusive
true
exact text
non-small cell lung cancer (NSCLC)
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
1760

source span

end: 1301
end exclusive: true
exact text: as a single agent, for the treatment of adults with hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib.
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 1131

source url

https://api.fda.gov/drug/label.json?search=id%3A%22161cb5e7-7955-45e5-bdde-9be94fdbe76a%22

spl effective date

2026-06-09

spl set id

c6080942-dee6-423e-b688-1272c2ae90d4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 11 · unclassified context

application numbers

BLA125477

brand names

CYRAMZA

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1509
end exclusive: true
exact text: a fluoropyrimidine. ( 1.3 ) as a single agent, for the treatment of adults with hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib. ( 1.4 ) 1.1 Gastric Cancer CYRAMZA ® , as a single agent or in combination with paclitaxel, is indicated for the treatment of adults with advanced or metastatic, gastric or gastro-esophageal junction (GEJ) a
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 1102

current approval status

not_reconciled

duplicate text group

dup-c34b9ce8ea338b1c21db

extraction review status

automated_candidate_pending_source_review

generic names

RAMUCIRUMAB

ind-span-5942f5283599031fddb1

label id

161cb5e7-7955-45e5-bdde-9be94fdbe76a

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
non-small cell lung cancer
definition span
end
1794
end exclusive
true
exact text
non-small cell lung cancer (NSCLC)
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
1760

source span

end: 1309
end exclusive: true
exact text: ( 1.4 )
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 1302

source url

https://api.fda.gov/drug/label.json?search=id%3A%22161cb5e7-7955-45e5-bdde-9be94fdbe76a%22

spl effective date

2026-06-09

spl set id

c6080942-dee6-423e-b688-1272c2ae90d4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 12 · positive indication candidate

application numbers

BLA125477

brand names

CYRAMZA

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1820
end exclusive: true
exact text: opyrimidine. ( 1.3 ) as a single agent, for the treatment of adults with hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib. ( 1.4 ) 1.1 Gastric Cancer CYRAMZA ® , as a single agent or in combination with paclitaxel, is indicated for the treatment of adults with advanced or metastatic, gastric or gastro-esophageal junction (GEJ) adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. 1.2 Non-Small Cell Lung Cancer CYRAMZA, in combination with erlotinib, is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have epiderm
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 1110

current approval status

not_reconciled

duplicate text group

dup-b9aa08432ae165b30859

extraction review status

automated_candidate_pending_source_review

generic names

RAMUCIRUMAB

ind-span-fbb78ccff8d2514dd203

label id

161cb5e7-7955-45e5-bdde-9be94fdbe76a

positive predicate support span

end: 1406
end exclusive: true
exact text: is indicated
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 1394

qualifier mentions

context exact
bination with paclitaxel, is indicated for the treatment of adults with advanced or metastatic, gastric or gastro-esophageal j
kind
age
polarity
not_inferred
span
end
1434
end exclusive
true
exact text
adults
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
1428
context exact
, is indicated for the treatment of adults with advanced or metastatic, gastric or gastro-esophageal junction (GEJ) adenocarcinoma
kind
biomarker
polarity
not_inferred
span
end
1462
end exclusive
true
exact text
metastatic
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
1452
context exact
h paclitaxel, is indicated for the treatment of adults with advanced or metastatic, gastric or gastro-esophageal junction (GEJ) adenocarcinoma
kind
stage_or_setting
polarity
not_inferred
span
end
1462
end exclusive
true
exact text
advanced or metastatic
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
1440
context exact
1.1 Gastric Cancer CYRAMZA ® , as a single agent or in combination with paclitaxel, is indicated for the treatment of adults with advanced or metastatic, gastric or gastro-esophageal junction (GEJ) adenocarcinoma with disease progression on or after prior fluoropyrimi
kind
regimen
polarity
not_inferred
span
end
1518
end exclusive
true
exact text
as a single agent or in combination with paclitaxel, is indicated for the treatment of adults with advanced or metastatic, gastric or gastro-esophageal junction (GEJ) adenocarci
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
1341

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
non-small cell lung cancer
definition span
end
1794
end exclusive
true
exact text
non-small cell lung cancer (NSCLC)
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
1760

source span

end: 1620
end exclusive: true
exact text: 1.1 Gastric Cancer CYRAMZA ® , as a single agent or in combination with paclitaxel, is indicated for the treatment of adults with advanced or metastatic, gastric or gastro-esophageal junction (GEJ) adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 1310

source url

https://api.fda.gov/drug/label.json?search=id%3A%22161cb5e7-7955-45e5-bdde-9be94fdbe76a%22

spl effective date

2026-06-09

spl set id

c6080942-dee6-423e-b688-1272c2ae90d4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 13 · positive indication candidate

application numbers

BLA125477

brand names

CYRAMZA

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2113
end exclusive: true
exact text: ent of adults with advanced or metastatic, gastric or gastro-esophageal junction (GEJ) adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. 1.2 Non-Small Cell Lung Cancer CYRAMZA, in combination with erlotinib, is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. CYRAMZA, in combination with docetaxel, is indicated for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. P
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 1421

current approval status

not_reconciled

duplicate text group

dup-76e543aa6a220d56c121

extraction review status

automated_candidate_pending_source_review

generic names

RAMUCIRUMAB

ind-span-d130bf7bc11b55a4e699

label id

161cb5e7-7955-45e5-bdde-9be94fdbe76a

positive predicate support span

end: 1704
end exclusive: true
exact text: is indicated
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 1692

qualifier mentions

context exact
ith erlotinib, is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tu
kind
age
polarity
not_inferred
span
end
1743
end exclusive
true
exact text
adults
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
1737
context exact
b, is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR)
kind
biomarker
polarity
not_inferred
span
end
1792
end exclusive
true
exact text
metastatic non-small cell lung cancer (NSCL
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
1749
context exact
(NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.
kind
biomarker
polarity
not_inferred
span
end
1891
end exclusive
true
exact text
EGFR) exon 19 deletions or exon 21 (L858R) s
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
1847
context exact
b, is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) e
kind
stage_or_setting
polarity
not_inferred
span
end
1794
end exclusive
true
exact text
metastatic non-small cell lung cancer (NSCLC)
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
1749
context exact
YRAMZA, in combination with erlotinib, is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.
kind
prior_therapy_or_line
polarity
not_inferred
span
end
1883
end exclusive
true
exact text
first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
1713
context exact
1.2 Non-Small Cell Lung Cancer CYRAMZA, in combination with erlotinib, is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substituti
kind
regimen
polarity
not_inferred
span
end
1840
end exclusive
true
exact text
in combination with erlotinib, is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor rec
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
1661

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
non-small cell lung cancer
definition span
end
1794
end exclusive
true
exact text
non-small cell lung cancer (NSCLC)
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
1760

source span

end: 1913
end exclusive: true
exact text: 1.2 Non-Small Cell Lung Cancer CYRAMZA, in combination with erlotinib, is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 1621

source url

https://api.fda.gov/drug/label.json?search=id%3A%22161cb5e7-7955-45e5-bdde-9be94fdbe76a%22

spl effective date

2026-06-09

spl set id

c6080942-dee6-423e-b688-1272c2ae90d4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 14 · positive indication candidate

application numbers

BLA125477

brand names

CYRAMZA

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2311
end exclusive: true
exact text: irst-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. CYRAMZA, in combination with docetaxel, is indicated for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. Patients with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 1714

current approval status

not_reconciled

duplicate text group

dup-53c69558ac12075be906

extraction review status

automated_candidate_pending_source_review

generic names

RAMUCIRUMAB

ind-span-ec0482b33040f4a1aa29

label id

161cb5e7-7955-45e5-bdde-9be94fdbe76a

positive predicate support span

end: 1966
end exclusive: true
exact text: is indicated
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 1954

qualifier mentions

context exact
mbination with docetaxel, is indicated for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) with dis
kind
age
polarity
not_inferred
span
end
1994
end exclusive
true
exact text
adults
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
1988
context exact
th docetaxel, is indicated for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemo
kind
biomarker
polarity
not_inferred
span
end
2043
end exclusive
true
exact text
metastatic non-small cell lung cancer (NSCL
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
2000
context exact
th docetaxel, is indicated for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemoth
kind
stage_or_setting
polarity
not_inferred
span
end
2045
end exclusive
true
exact text
metastatic non-small cell lung cancer (NSCLC)
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
2000
context exact
CYRAMZA, in combination with docetaxel, is indicated for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy.
kind
regimen
polarity
not_inferred
span
end
2102
end exclusive
true
exact text
in combination with docetaxel, is indicated for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chem
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
1923

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
non-small cell lung cancer
definition span
end
1794
end exclusive
true
exact text
non-small cell lung cancer (NSCLC)
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
1760

source span

end: 2111
end exclusive: true
exact text: CYRAMZA, in combination with docetaxel, is indicated for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy.
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 1914

source url

https://api.fda.gov/drug/label.json?search=id%3A%22161cb5e7-7955-45e5-bdde-9be94fdbe76a%22

spl effective date

2026-06-09

spl set id

c6080942-dee6-423e-b688-1272c2ae90d4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 15 · unclassified context

application numbers

BLA125477

brand names

CYRAMZA

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2533
end exclusive: true
exact text: . CYRAMZA, in combination with docetaxel, is indicated for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. Patients with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA. 1.3 Colorectal Cancer CYRAMZA, in combination with FOLFIRI (irinotecan, folinic acid, and fluorouracil), is indicated for the treatment of adults with metastatic colorectal cancer (mCRC) with disease
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 1912

current approval status

not_reconciled

duplicate text group

dup-4f4bed3e6c113584ef82

extraction review status

automated_candidate_pending_source_review

generic names

RAMUCIRUMAB

ind-span-2edc0c73160feba4ece6

label id

161cb5e7-7955-45e5-bdde-9be94fdbe76a

positive predicate support span

Source null

qualifier mentions

context exact
Patients with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations should have disease progression on F
kind
biomarker
polarity
not_inferred
span
end
2204
end exclusive
true
exact text
EGFR) or anaplastic lymphoma kinase (ALK) ge
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
2160

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
non-small cell lung cancer
definition span
end
1794
end exclusive
true
exact text
non-small cell lung cancer (NSCLC)
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
1760

source span

end: 2333
end exclusive: true
exact text: Patients with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA.
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 2112

source url

https://api.fda.gov/drug/label.json?search=id%3A%22161cb5e7-7955-45e5-bdde-9be94fdbe76a%22

spl effective date

2026-06-09

spl set id

c6080942-dee6-423e-b688-1272c2ae90d4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 16 · positive indication candidate

application numbers

BLA125477

brand names

CYRAMZA

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2826
end exclusive: true
exact text: l growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA. 1.3 Colorectal Cancer CYRAMZA, in combination with FOLFIRI (irinotecan, folinic acid, and fluorouracil), is indicated for the treatment of adults with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. 1.4 Hepatocellular Carcinoma CYRAMZA, as a single agent, is indicated for the treatment of adults with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of ≥400 ng/mL and have been t
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 2134

current approval status

not_reconciled

duplicate text group

dup-16ea27752edebd37c2a1

extraction review status

automated_candidate_pending_source_review

generic names

RAMUCIRUMAB

ind-span-fd62ba88e081ca14aefb

label id

161cb5e7-7955-45e5-bdde-9be94fdbe76a

positive predicate support span

end: 2451
end exclusive: true
exact text: is indicated
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 2439

qualifier mentions

context exact
acid, and fluorouracil), is indicated for the treatment of adults with metastatic colorectal cancer (mCRC) with disease progr
kind
age
polarity
not_inferred
span
end
2479
end exclusive
true
exact text
adults
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
2473
context exact
luorouracil), is indicated for the treatment of adults with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab
kind
biomarker
polarity
not_inferred
span
end
2528
end exclusive
true
exact text
metastatic colorectal cancer (mCRC) with di
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
2485
context exact
luorouracil), is indicated for the treatment of adults with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab,
kind
stage_or_setting
polarity
not_inferred
span
end
2530
end exclusive
true
exact text
metastatic colorectal cancer (mCRC) with dise
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
2485
context exact
1.3 Colorectal Cancer CYRAMZA, in combination with FOLFIRI (irinotecan, folinic acid, and fluorouracil), is indicated for the treatment of adults with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, a
kind
regimen
polarity
not_inferred
span
end
2544
end exclusive
true
exact text
in combination with FOLFIRI (irinotecan, folinic acid, and fluorouracil), is indicated for the treatment of adults with metastatic colorectal cancer (mCRC) with disease progressio
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
2365

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
non-small cell lung cancer
definition span
end
1794
end exclusive
true
exact text
non-small cell lung cancer (NSCLC)
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
1760

source span

end: 2626
end exclusive: true
exact text: 1.3 Colorectal Cancer CYRAMZA, in combination with FOLFIRI (irinotecan, folinic acid, and fluorouracil), is indicated for the treatment of adults with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 2334

source url

https://api.fda.gov/drug/label.json?search=id%3A%22161cb5e7-7955-45e5-bdde-9be94fdbe76a%22

spl effective date

2026-06-09

spl set id

c6080942-dee6-423e-b688-1272c2ae90d4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 17 · positive indication candidate

application numbers

BLA125477

brand names

CYRAMZA

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2848
end exclusive: true
exact text: orouracil), is indicated for the treatment of adults with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. 1.4 Hepatocellular Carcinoma CYRAMZA, as a single agent, is indicated for the treatment of adults with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of ≥400 ng/mL and have been treated with sorafenib.
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 2427

current approval status

not_reconciled

duplicate text group

dup-e98a61a3b3492e461e35

extraction review status

automated_candidate_pending_source_review

generic names

RAMUCIRUMAB

ind-span-8086798f61ce5e0eefd4

label id

161cb5e7-7955-45e5-bdde-9be94fdbe76a

positive predicate support span

end: 2696
end exclusive: true
exact text: is indicated
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 2684

qualifier mentions

context exact
RAMZA, as a single agent, is indicated for the treatment of adults with hepatocellular carcinoma (HCC) who have an alpha fetop
kind
age
polarity
not_inferred
span
end
2724
end exclusive
true
exact text
adults
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
2718
context exact
1.4 Hepatocellular Carcinoma CYRAMZA, as a single agent, is indicated for the treatment of adults with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of ≥400 ng/mL and have been treated with sorafenib.
kind
regimen
polarity
not_inferred
span
end
2842
end exclusive
true
exact text
as a single agent, is indicated for the treatment of adults with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of ≥400 ng/mL and have been treated with sora
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
2665

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
non-small cell lung cancer
definition span
end
1794
end exclusive
true
exact text
non-small cell lung cancer (NSCLC)
label id
161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start
1760

source span

end: 2848
end exclusive: true
exact text: 1.4 Hepatocellular Carcinoma CYRAMZA, as a single agent, is indicated for the treatment of adults with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of ≥400 ng/mL and have been treated with sorafenib.
label id: 161cb5e7-7955-45e5-bdde-9be94fdbe76a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3cdb1aed92fdcaf91bdee74bb7940b55f89f2f83a9bae66dca7dfbf1cc1f254d
start: 2627

source url

https://api.fda.gov/drug/label.json?search=id%3A%22161cb5e7-7955-45e5-bdde-9be94fdbe76a%22

spl effective date

2026-06-09

spl set id

c6080942-dee6-423e-b688-1272c2ae90d4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Preserved source evidence · Not medical advice